QT Vascular (QTVLF) is a global company engaged in the development and commercialization of innovative devices for the minimally invasive treatment of vascular disease without the use of permanent implants (stents).
TriReme Medical, TriReme Medical (Singapore) and Quattro Vascular Pte, Ltd are wholly-owned subsidiaries of QT Vascular (QTVLF)
Most Americans are familiar with heart disease and with the consequences of blockages in the vessels that carry blood to and from the heart. But few people realize that blockages caused by a buildup of plaque and cholesterol affect more than coronary arteries. Arteries throughout the body carry oxygen-rich blood away from the heart, so blockages can occur in all arteries with serious effects. QT Vascular (QTVLF) and it's various FDA and EU approved coronary balloon catheter's and other coronary angioplasty products are first in class cutting edge solutions for the treatment of blocked arteries.
QT Vascular (QTVLF) HIGHLIGHTS
-QTVLF revenue for 2016 was $10.6 million (this was audited...very transparent company)
-QTVLF revenue for the 3 month period ending ended June 30, 2017 was over $3.5 million versus $2.3 million for the same time frame a year ago. An increase of over $1.1 million or almost 30% as the new distribution agreement.the world’s leading medical device company, Medtronic kicked in along with increased US sales! (Strong Buy Signal!)
-QTVLF revenue for the 6 month period ending ended June 30, 2017 was $6.7 million versus $5.9 million a year ago. Another increase and it is only going to get better! (Strong Buy Signal!)
-QTVLF has assets of US$6.3 million as of 31 December 2016
-QTVLF CEO says debt at the end of 2016 was slashed by approximately US$7.8 million from US$19.2 million in 2015 to US$11.4 million. With US sales growing and the new agreement for distribution with the world’s leading medical device company global giant Medtronics CEO says debt will continue to be taken out through 2017! (Strong Buy Signal!)
-QTVLF is backed by the Singaporean government who is fast becoming a world leader in promoting life sciences, investing heavily in firms and in the sort of infrastructure that will support the industry throught it's state-financed biomedical sciences investment fund (BMSIF)
-QTVLF also backed by other major established and reputable shareholders include Three Arch Partners, a healthcare fund which has internally incubated more than a dozen start-up healthcare companies AND Luminor Pacific Fund 1 is a private equity healthcare-focused fund based in Singapore approved under the Singapore government’s global investor programme.
-QTVLF following the AWESOME new 2017 agreement with Medtronic that went into effect March 1st 2017 the company then received an offer for up to $20 MILLION CAPITAL COMMITMENT on favorable terms from US based New York private investment group GEM GLOBAL. GEM is a USD 3.4 billion investment group having completed 372 transactions in 70 countries. (Strong Buy Signal!)
-QTVLF CEO says they are currently selling their coronary balloon catheter's and other coronary angioplasty products to over 150 Hospitals in the United States alone! (Strong Buy Signal!)
-QTVLF has an estimated 70% insider and foreign institutional ownership including the Singaporean state-financed biomedical sciences investment fund
-QTVLF cutting edge FDA and European Union approved coronary balloon catheter's and other coronary angioplasty products are competing and beating out major global pharmaceutical companies like Abbott Laboratories and Boston Scientific Corporation who also manufacture stent and balloon angioplasty products
-QTVLF has filed over 40 patents filed worldwide on it's coronary balloon catheter's and other coronary angioplasty products
-QTVLF Awards and Recognition: company received a Certificate of Special Congressional Recognition from U.S. Congressman Jerry McNerney
-QTVLF Awards and Recognition the company subsidiary, TriReme US, was recognised by the City of Pleasanton where it is based for its ongoing contributions to the strength of the economy locally and positive impacts to the quality of life globally
-QTVLF is the first ever Singapore based biotech medical company to receive approval US Food and Drug Administration (“FDA”) for an interventional medical device developed in Singapore
-QTVLF revenues would have been even more in 2016 but the company switched from Cordis to the world’s leading medical device company, Medtronic. Despite this disruption CEO says the company increased gross profit by 11% (Strong Buy Signal!)
-QTVLF is heading towards being CASH FLOW POSITIVE, reduced loss from US$53.1 million in FY2015 to US$12.0 million in FY2016, That is phenomenal! With the new distribution agreement with the world’s leading medical device company, Medtronic complete debt elimination and massive revenue increases will continue! (Strong Buy Signal!)
-QTVLF CEO says that US sales in 2106 of it's coronary products increased a WHOPPING 49% equalling an increased per sales representative efficiency of 114% (Strong Buy Signal!)
-QTVLF PRODUCTS are in DEMAND, CEO says they working hard to increase production in support of the new distribution agreement.the world’s leading medical device company, Medtronic. (Strong Buy Signal!)
-QTVLF CEO says that in 2016 the US remained the companies largest market, accounting for 86.9% of total revenue. Sales to Europe improved during the year. Europe accounted for 5.8% of total revenue with US$620,000 in sales, compared with US$426,000 a year ago. With the new 2017 agreement with the world’s leading medical device company, Medtronic global and European sales are forecast to substantially increase!
-QTVLF has generated awesome positive clinical data It's coronary angioplasty product Chocolate PTA achieved a 0% failure rate during a human trial study on 22 patients in Germany and New Zealand for one year, and subsequent follow-ups showed no complications. Data from the first 350 patients of a separate human trial study of the Chocolate PTA in the United States showed high rates of treatment success and limb preservation. (Strong Buy Signal!)CEO says "We are delighted with the angiographic results of Chocolate Heart™ showing maintenance of patency at two years," stated Eitan Konstantino, PhD, CEO of QT Vascular. "Those patients are doing well without a stent in their heart and this is exactly what we are here for." (Strong Buy Signal!)
CEO also said "in keeping with our commitment to proving the clinical value of our technology, we announced the 12 month outcomes of the Chocolate Heart® First-in-Human Study, the final results of the US registry of Chocolate® PTA known as Chocolate BAR, and the final results of the Chocolate Touch® First-in-Human trial known as ENDURE. The results of all of these studies added significantly to the body of evidence supporting the unique benefits of the Chocolate® platform" (Strong Buy Signal!)
-QTVLF In Europe has ALSO obtained CE mark clearance for Chocolate Heart®, the coronary drug-coated balloon (Strong Buy Signal!)
-QTVLF new cutting edge proprietary technologies: CEO on the NEW revolutionary drug coated coronary products "The area of peripheral arterial disease remains very much under-treated. While stents are used to treat some of these patients, there is a growing preference for therapies such as drug-coated balloons that do not involve placing a permanent implant. Sales of drug coated balloons are estimated to have surpassed US$300 million in 2016 in the US market and the global market will surpass US$1 billion in sales by 20202 . QT Vascular is well positioned to benefit from the increased adoption of drug-coated balloons. Chocolate Touch® has received full FDA clearance to begin the pivotal trial. Upon approval, this would make Chocolate Touch® only the 4th such device to be approved in the US.
The final results of Chocolate Touch®’s first-in-human trials are similar to the best-in class devices. The Company’s recently announced distribution agreement with Medtronic, along with the recent launch of the Group’s latest generation coronary device, Chocolate XD®, bode well for supporting our growth in FY2017." (Strong Buy Signal!)
-QTVLF while conducting most of it's business in the US it is strategically located in Singapore, a hub of Asia and have access to the markets in the PRC and Japan through distribution agreements. The business-friendly environment in Singapore will allow the use Singapore as the Asian hub for the companies Asian focused marketing activities, revenues in Asia which are forecast to grow significantly with the companies new outreach into mainland ChinaThe companies top markets include the USA and growing medical device markets, especially in Europe, China, Japan and other parts of Asia. CEO says "Our products are focused on the treatment of cardiovascular diseases, which are the number one cause of death globally, and half of all such cases are estimated to occur in Asia"
-QTVLF expansion into mainland China, a distribution agreement with Weihai Weigao Medical Devices, Ltd. for the distribution of our peripheral products, the GliderXtreme PTA, GliderfleX PTA and Chocolate PTA coronary products in the People’s Republic of China.Weihai Weigao Medical Devices is a leading supplier of medical devices in China.Weihai Weigao has an extensive sales network comprising 25 sales offices, 38 customer liaison centers and 170 municipal representative offices. As at the date of this report, Weihai Weigao has an total customer base of 5,159 (including 3,090 hospitals, 414 blood stations, 611 other medical units and 1,044 distributors). (Strong Buy Signal!)
-QTVLF Top Management CEO Dr. Konstantino was the CEO & COO of Advanced Stent Technologies (“AST”), a bifurcation stent company that was acquired by Boston Scientific in 2004. He co-invented the Petal bifurcation stent that is currently with Boston Scientific.
-QTVLF Top Managementb Executive Vice President Ms. Pizarro spent 10 years at Boston Scientific, Neurovascular Division, where she led neurovascular minimally invasive device research (intracranial implantable devices) and development projects from concept to commercialization. Prior to joining TriReme, Ms. Pizarro was the Director of Research and Development at AngioScore Inc., where she led the development of cardiovascular and peripheral devices
QT Vascular (QTVLF) Company Description
QT Vascular Ltd., together with its subsidiaries, designs, assembles, and distributes therapeutic solutions for the minimally invasive treatment of complex vascular diseases. The company offers coronary products, including Chocolate percutaneous transluminal coronary angioplasty (PTCA) balloon catheter to reduce vessel trauma by providing balloon inflation; and Glider PTCA for the treatment of various complex lesions.
It also provides Chocolate percutaneous transluminal angioplasty (PTA) balloon catheter for the treatment of blocked arteries; Chocolate Touch, a drug-coated balloon catheter; GliderfleX PTA for treating distal peripheral vessels; and GliderXtreme PTA balloon catheter that targets complex lesions in the distal peripheral vasculature.
The company sells its products through its direct sales team. It has operations in the United States, Singapore, Japan, Europe, China, Australia, and Hong Kong. QT Vascular Ltd. was incorporated in 2013 and is based in Singapore.
Check out QT Vascular Ltd. (QTVLF) awesome website
I do not know of any biotech stock or otherwise that is trading around a penny that has been recognized and received an award from the US Congress and from a US City and that also has multiple products ALREADY APPROVED by both the FDA and the EU. With it's products already being commercialized and new cutting edge FDA trials approved and happening the share price is only going to rise from this point.
Once again it is VERY RARE to find a biotech of this calibre trading so low, but it will not last, I believe that the the potential for significant gains from this level is very good!
Buying share of QT Vascular Ltd. (QTVLF) at this price point is for me a no-brainer!
DD posted by Darth Trader Stocks on October 8th 2017